Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GLOBE LIFE INC.GL · Entity 3408 | Director | January 02, 2024 | January 03, 2024 |
| Immix Biopharma, Inc.IMMX · Entity 4958 | Director | May 22, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GLOBE LIFE INC.
Report date January 02, 2024 · Filed January 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $122.06 · Expires 2031-01-02 | Direct | 1,728 |
Reported balance
After 2024-01-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-02 · Grant · Acquired 1,728 · Balance 1,728 |
| Common StockSEC Table I · non-derivative | Direct | 80,284.7297 |
Reported balance
Holding disclosure · report date 2024-01-02 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 80,284.7297 |
| Common StockSEC Table I · non-derivative | IndirectNot Applicable | 0 |
Reported balance
Holding disclosure · report date 2024-01-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 0 |
Immix Biopharma, Inc.
Report date May 22, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,705 |
Reported balance
After 2026-05-22 transaction · row 1
1 source rowRow 1 · 2026-05-22 · Grant · Acquired 6,250 · Balance 28,705 F1: The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.78 · Expires 2036-05-22 | Direct | 12,500 |
Reported balance
After 2026-05-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-22 · Grant · Acquired 12,500 · Balance 12,500 F2: The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer.
F2: The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 22, 2026 Filed May 29, 2026 21:05 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $8.78 | $0.00 |
DisclosureSEC source: 0001493152-26-026423 · ownership.xml · derivative · entry 2 BUCHAN JANE · CIK 0001342502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2036-05-22 F2 · derivative.exercise_date: The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date. Read SEC document |
| May 22, 2026 Filed May 29, 2026 21:05 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-026423 · ownership.xml · nonDerivative · entry 1 BUCHAN JANE · CIK 0001342502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,705 F1 · shares: The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 20, 2025 Filed Jun 23, 2025 20:57 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Option (Right to Buy) · Derivative | 33,000 | $0.00 Strike: $2.24 | $0.00 |
DisclosureSEC source: 0001641172-25-016110 · ownership.xml · derivative · entry 2 BUCHAN JANE · CIK 0001342502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2035-06-20 F1 · derivative.exercise_date: The Stock Option will vest in twelve (12) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 11, 2024 Filed Jun 21, 2024 21:45 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Option (Right to Buy) · Derivative | 33,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001493152-24-024822 · ownership.xml · derivative · entry 2 BUCHAN JANE · CIK 0001342502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2034-06-11 F1 · derivative.exercise_date: The Stock Option will vest in twelve (12) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 20, 2024 Filed May 20, 2024 21:25 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantCommon Stock | 1,127 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-24-020779 · ownership.xml · nonDerivative · entry 2 BUCHAN JANE · CIK 0001342502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,455 F3 · price: Received in exchange for shares of common stock of Nexcella, Inc. which were held by the Reporting Person, which entity was merged with and into the Issuer on May 20, 2024, with the Issuer continuing as the surviving entity. Read SEC document |
| May 15, 2024 Filed May 20, 2024 21:25 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Option (Right to Buy) · Derivative | 24,153 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0001493152-24-020779 · ownership.xml · derivative · entry 4 BUCHAN JANE · CIK 0001342502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,153 Underlying: Common Stock · 24,153 shares Expires 2033-05-26 F1 · kind: Issued to replace prior awards held by the Reporting Person in Nexcella, Inc., in contemplation of the merger of Nexcella, Inc. and the Issuer, which became effective on May 20, 2024. F4 · derivative.exercise_date: The Stock Option will vest in thirteen (13) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 15, 2024 Filed May 20, 2024 21:25 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Option (Right to Buy) · Derivative | 20,436 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0001493152-24-020779 · ownership.xml · derivative · entry 3 BUCHAN JANE · CIK 0001342502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,436 Underlying: Common Stock · 20,436 shares Expires 2033-05-26 F1 · kind: Issued to replace prior awards held by the Reporting Person in Nexcella, Inc., in contemplation of the merger of Nexcella, Inc. and the Issuer, which became effective on May 20, 2024. Read SEC document |
| May 15, 2024 Filed May 20, 2024 21:25 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantCommon Stock | 1,332 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-020779 · ownership.xml · nonDerivative · entry 1 BUCHAN JANE · CIK 0001342502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,332 F1 · kind: Issued to replace prior awards held by the Reporting Person in Nexcella, Inc., in contemplation of the merger of Nexcella, Inc. and the Issuer, which became effective on May 20, 2024. F2 · shares: Restricted Stock Awards which will vest in thirteen (13) equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 20:41 UTC | GLOBE LIFE INC. GL · Entity 3408 | GrantDirector Stock Option (Right to Buy) · Derivative | 1,728 | $0.00 Strike: $122.06 | $0.00 |
DisclosureSEC source: 0001062993-24-000169 · form4.xml · derivative · entry 3 BUCHAN JANE · CIK 0001342502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,728 Underlying: Common Stock · 1,728 shares Expires 2031-01-02 Read SEC document |
| December 12, 2023 Filed Dec 13, 2023 21:47 UTC | GLOBE LIFE INC. GL · Entity 3408 | SaleCommon Stock | 1,000 | $124.50 | $124,500.00 |
DisclosureSEC source: 0001062993-23-022528 · form4.xml · nonDerivative · entry 1 BUCHAN JANE · CIK 0001342502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,284.7297 Read SEC document |
| November 21, 2023 Filed Nov 22, 2023 14:54 UTC | GLOBE LIFE INC. GL · Entity 3408 | GiftCommon Stock | 10 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-021321 · form4.xml · nonDerivative · entry 1 BUCHAN JANE · CIK 0001342502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,284.7297 Read SEC document |
| November 16, 2023 Filed Nov 17, 2023 21:09 UTC | GLOBE LIFE INC. GL · Entity 3408 | GiftCommon Stock | 425 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-021107 · form4.xml · nonDerivative · entry 1 BUCHAN JANE · CIK 0001342502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,294.7297 F1 · balance_after: Includes 296.593 dividend right restricted stock units acquired upon restricted stock units in 2023. Read SEC document |
| September 07, 2023 Filed Sep 11, 2023 21:18 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | PurchaseCommon Stock | 20,000 | $2.46 | $49,226.00 |
DisclosureSEC source: 0001493152-23-032280 · ownership.xml · nonDerivative · entry 1 BUCHAN MELISSA JANE · CIK 0001342502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F1 · price: This figure is the weighted average sales price of multiple trades ranging from $2.39 to $2.49 per share. The Reporting Person undertakes to provide the staff of the Securities and Exchange Commission, Immix Biopharma, Inc. or any security holder of Immix Biopharma, Inc. full information about the number of shares sold at each separate price upon request. Read SEC document |
| August 11, 2023 Filed Aug 14, 2023 20:15 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Options · Derivative | 20,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001493152-23-028475 · ownership.xml · derivative · entry 1 BUCHAN MELISSA JANE · CIK 0001342502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-08-11 F1 · derivative.exercise_date: Options vest monthly over 12 months from the date of grant. Read SEC document |
| June 30, 2023 Filed Jun 30, 2023 14:48 UTC | GLOBE LIFE INC. GL · Entity 3408 | GiftCommon Stock | 235 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-014213 · form4.xml · nonDerivative · entry 1 BUCHAN MELISSA JANE · CIK 0001342502 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,423.1367 Read SEC document |
| March 16, 2023 Filed Mar 16, 2023 21:35 UTC | GLOBE LIFE INC. GL · Entity 3408 | SaleCommon Stock | 1,900 | $105.95 | $201,305.00 |
DisclosureSEC source: 0001062993-23-007089 · form4.xml · nonDerivative · entry 1 BUCHAN MELISSA JANE · CIK 0001342502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,658.1367 Read SEC document |
| January 03, 2023 Filed Jan 10, 2023 00:07 UTC | GLOBE LIFE INC. GL · Entity 3408 | GrantCommon Stock | 1,422 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-000748 · form4.xml · nonDerivative · entry 1 BUCHAN MELISSA JANE · CIK 0001342502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,558.1367 Read SEC document |
| November 29, 2022 Filed Nov 29, 2022 23:06 UTC | GLOBE LIFE INC. GL · Entity 3408 | GiftCommon Stock | 430 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-022943 · form4.xml · nonDerivative · entry 1 BUCHAN MELISSA JANE · CIK 0001342502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,136.1367 F1 · balance_after: Includes 143.7898 dividend right restricted stock units acquired upon restricted stock units since date of last report. Read SEC document |
| July 14, 2022 Filed Jul 18, 2022 10:05 UTC | Immix Biopharma, Inc. IMMX · Entity 4958 | GrantStock Options · Derivative | 16,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001493152-22-019502 · ownership.xml · derivative · entry 1 BUCHAN MELISSA JANE · CIK 0001342502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,000 Underlying: Common Stock · 16,000 shares Expires 2032-07-14 F1 · derivative.exercise_date: Options vest monthly over 12 months from date of grant. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 19:48 UTC | GLOBE LIFE INC. GL · Entity 3408 | GiftCommon Stock | 265 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-015548 · form4.xml · nonDerivative · entry 1 BUCHAN MELISSA JANE · CIK 0001342502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,422.3469 F1 · balance_after: Includes 147.856 dividend right restricted stock units acquired upon restricted stock units since date of last report. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 15:26 UTC | GLOBE LIFE INC. GL · Entity 3408 | GrantCommon Stock | 1,791 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-000520 · form4.xml · nonDerivative · entry 1 BUCHAN MELISSA JANE · CIK 0001342502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,539.4909 Read SEC document |
| December 21, 2021 Filed Dec 21, 2021 20:37 UTC | GLOBE LIFE INC. GL · Entity 3408 | GiftCommon Stock | 570 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-21-013301 · form4.xml · nonDerivative · entry 1 BUCHAN MELISSA JANE · CIK 0001342502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,748.4909 Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 16:48 UTC Amendment | GLOBE LIFE INC. GL · Entity 3408 | SaleCommon Stock | 1,700 | $92.08 | $156,532.26 |
DisclosureSEC source: 0001062993-21-010220 · form4a.xml · nonDerivative · entry 1 BUCHAN MELISSA JANE · CIK 0001342502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,318.4909 F1 · balance_after: Beneficial ownership amount amended so as to include 148.4052 dividend right restricted stock units acquired upon restricted stock units since date of last report. Original filing was timely made. Read SEC document |
| November 02, 2021 Filed Nov 4, 2021 16:23 UTC | GLOBE LIFE INC. GL · Entity 3408 | SaleCommon Stock | 1,700 | $92.08 | $156,532.26 |
DisclosureSEC source: 0001062993-21-010218 · form4.xml · nonDerivative · entry 1 BUCHAN MELISSA JANE · CIK 0001342502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,170.0857 Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 20:22 UTC | GLOBE LIFE INC. GL · Entity 3408 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 11,667 | $0.00 Strike: $54.16 | $0.00 |
DisclosureSEC source: 0001665773-21-000169 · edgar.xml · derivative · entry 4 BUCHAN MELISSA JANE · CIK 0001342502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,667 shares Expires 2022-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 20:22 UTC | GLOBE LIFE INC. GL · Entity 3408 | SaleCommon Stock | 11,667 | $105.89 | $1,235,426.80 |
DisclosureSEC source: 0001665773-21-000169 · edgar.xml · nonDerivative · entry 2 BUCHAN MELISSA JANE · CIK 0001342502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,870.0857 F1 · price: Sales at prices ranging from $105.68 per share to $106.41 per share. F2 · price: Reporting person will provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the issuer or any security holder of the issuer. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 20:22 UTC | GLOBE LIFE INC. GL · Entity 3408 | Exercise / conversionCommon Stock | 11,667 | $54.16 | $631,884.72 |
DisclosureSEC source: 0001665773-21-000169 · edgar.xml · nonDerivative · entry 1 BUCHAN MELISSA JANE · CIK 0001342502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,537.0857 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · balance_after: Includes 137.4653 dividend right restricted stock units acquired upon restricted stock units since date of last report. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 23:15 UTC | GLOBE LIFE INC. GL · Entity 3408 | GrantCommon Stock | 1,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001665773-21-000010 · edgar.xml · nonDerivative · entry 1 BUCHAN MELISSA JANE · CIK 0001342502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,732.6204 F1 · balance_after: Includes 282.481 dividend right restricted stock units acquired upon restricted stock units since date of last report. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 00:51 UTC | GLOBE LIFE INC. GL · Entity 3408 | GrantDirector Stock Option (Right to Buy) · Derivative | 8,626 | $0.00 Strike: $105.56 | $0.00 |
DisclosureSEC source: 0001665773-20-000009 · edgar.xml · derivative · entry 3 BUCHAN MELISSA JANE · CIK 0001342502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,626 Underlying: Common Stock · 8,626 shares Expires 2027-01-02 Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 20:57 UTC | GLOBE LIFE INC. TMK · Entity 3408 | GrantDirector Stock Option (Right to Buy) · Derivative | 9,474 | $0.00 Strike: $76.37 | $0.00 |
DisclosureSEC source: 0001183084-19-000008 · edgar.xml · derivative · entry 3 BUCHAN MELISSA JANE · CIK 0001342502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,474 Underlying: Common Stock · 9,474 shares Expires 2026-01-02 Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 17:41 UTC | GLOBE LIFE INC. TMK · Entity 3408 | GrantCommon Strock | 2,606 | $0.00 | $0.00 |
DisclosureSEC source: 0001183084-18-000021 · edgar.xml · nonDerivative · entry 1 BUCHAN MELISSA JANE · CIK 0001342502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,241.4906 F1 · balance_after: Includes 220.1046 dividend right restricted stock units acquired upon restricted stock units since date of last report. Read SEC document |
| January 03, 2017 Filed Jan 6, 2017 21:51 UTC | GLOBE LIFE INC. TMK · Entity 3408 | GrantCommon Strock | 3,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001183084-17-000008 · edgar.xml · nonDerivative · entry 1 BUCHAN MELISSA JANE · CIK 0001342502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,415.386 Read SEC document |
| November 14, 2016 Filed Nov 14, 2016 18:38 UTC | GLOBE LIFE INC. TMK · Entity 3408 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 13,500 | $0.00 Strike: $19.89 | $0.00 |
DisclosureSEC source: 0001183084-16-000454 · edgar.xml · derivative · entry 4 BUCHAN MELISSA JANE · CIK 0001342502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,500 shares Expires 2017-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Previously reported as option for 6,000 shares at an exercise price of $44.76 per share, but was adjusted to reflect 3-for-2 stock splits paid in the form of 50% stock dividend occuring on July 1, 2011 and July 1, 2014. Read SEC document |
| November 14, 2016 Filed Nov 14, 2016 18:38 UTC | GLOBE LIFE INC. TMK · Entity 3408 | SaleCommon Strock | 3,825 | $71.12 | $272,020.23 |
DisclosureSEC source: 0001183084-16-000454 · edgar.xml · nonDerivative · entry 2 BUCHAN MELISSA JANE · CIK 0001342502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,235.386 F2 · price: sales at prices ranging from $71.015 per share to $71.29 per share. F3 · price: Reporting person will provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the issuer or any security holder of the issuer. Read SEC document |
| November 14, 2016 Filed Nov 14, 2016 18:38 UTC | GLOBE LIFE INC. TMK · Entity 3408 | Exercise / conversionCommon Stock | 13,500 | $19.89 | $268,560.90 |
DisclosureSEC source: 0001183084-16-000454 · edgar.xml · nonDerivative · entry 1 BUCHAN MELISSA JANE · CIK 0001342502 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,060.386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 242.9893 shares acquired through brokerage dividend reinvestment plan since date of last report. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.